Topics

A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients

2019-08-18 20:09:32 | BioPortfolio

Summary

Treatment will start with dose escalation in addition to Standard of Care (steroid therapy with or without additional therapies) .

At the conclusion of the dose escalation segment of the study, if the 300 mg Cannabidiol dose level/placebo is deemed safe for two weeks with Standard of care dose of steroids, patients will continue receiving this 300 mg dose/placebo for an additional period of 3 months. Weekly tapering off of steroids will then commence and will be carried out .

Three months after starting treatment with Cannabidiol an interim analysis to evaluate Cannabidiol's safety and efficacy will be carried out and treatment assignment group may be changed (according to response confirmation)

Description

Individual patient Standard of Care (steroid therapy with or without additional therapies) will be administered in a stable fashion during the first weeks of the study in addition to increasing doses of Cannabidiol or placebo ( in a double blind manner. Dosage of Cannabidiol will start at 25 mg twice a day and will be increased every two days, if no side effects are observed, to 50 mg twice a day, 100 mg twice a day and finally to 150 mg twice a day Cannabidiol respectively. Treatment will be given with food. Identical placebo will be administered in the placebo arm. In stage 1,both patient and investigator will be blinded to treatment modalities.

At the conclusion of the dose escalation segment of the study, if the 300 mg Cannabidiol dose level/placebo is deemed safe for two weeks with Standard of care dose of steroids, patients will continue receiving this 300 mg dose/placebo for an additional period of 3 months. Weekly tapering off of steroids will then commence and will be carried out .

Three months after starting treatment with Cannabidiol an interim analysis to evaluate Cannabidiol's safety and efficacy will be carried out by an independent assessor not associated with the study .At the conclusion of this interim analysis, Cannabidiol Non-responders will be removed from the trial, and Placebo Non-responders will be switched over to Cannabidiol.

If a patient flares, then his/her code will be opened by the unblinded observer. If the subject has been administered placebo, then he/she will be crossed over to the Cannabidiol arm. If the subject has been administered Cannabidiol, then he/she will be restarted on Standard of care prednisone in addition to Cannabidiol or removed from study, depending on the severity of the flare-up.

Study Design

Conditions

Steroid Dependent Crohn's Disease

Intervention

Cannabidiol , synthetic form, Placebo

Location

Meir Medical Center
Kfar Saba
Israel

Status

Recruiting

Source

Stero Biotechs Ltd.

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-08-18T20:09:32-0400

Clinical Trials [2306 Associated Clinical Trials listed on BioPortfolio]

Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease

To date, few studies have assessed the efficacy and safety of Cannabinoids, compounds derived from the Cannabis plant, in patients with Crohn's disease. Our study seeks to pilot a randomiz...

Cannabidiol for Inflammatory Bowel Disease

There are many anecdotal reports about improvement of Inflammatory bowel diseases (IBD) with cannabis smoking. The most effective anti inflammatory compound known today is cannabidiol. ca...

A Clinical Trial on the Antipsychotic Properties of Cannabidiol

The purpose of this study is to determine whether cannabidiol, a herbal cannabinoid, is effective in the treatment of acute schizophrenic or schizophreniform psychosis in a placebo-control...

OMS721 Treatment of Steroid-Dependent Glomerulopathies

The purpose of this study is to evaluate the effect of OMS721 in subjects with steroid-dependent IgA nephropathy (IgAN), lupus nephritis, membranous nephropathy (MN), and C3 glomerulopathy...

Retarded Phosphatidylcholine in Steroid-Dependent Chronic Active Ulcerative Colitis

The purpose of this study is to evaluate if retarded release phosphatidylcholine is an effective alternative to steroid dependent or -refractory course in chronic active ulcerative colitis...

PubMed Articles [27182 Associated PubMed Articles listed on BioPortfolio]

Acute abdominal pain in patients with Crohn's disease: what urgent imaging tests should be done?

Crohn's disease is an autoimmune disease that predominantly affects the gastrointestinal tract. Crohn's disease is diagnosed at a young age and runs a chronic course with acute flare-ups. When patient...

Should we resect the mesentery in ileocolic Crohn's disease ? - A response to "A warning about the role of extended mesenteric resection in Crohn's disease recurrence".

Lower Gastrointestinal Conditions: Inflammatory Bowel Disease.

Inflammatory bowel disease (IBD) is a group of diseases that result from an abnormal response to intestinal microbes in a genetically susceptible host. The two major forms are Crohn disease and ulcera...

Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease.

Early treatment of Crohn's disease (CD) is required to optimize patient outcomes. To this end, we need to gain a better understanding of the molecular changes at the onset of CD.

High-Risk Ileocolic Anastomoses for Crohn's Disease: When Is Diversion Indicated?

Patients with Crohn's disease undergoing ileocolectomy and primary anastomosis are often at increased risk of anastomotic leak. We aimed to determine whether diverting ileostomy was protective against...

Medical and Biotech [MESH] Definitions

A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.

A condition characterized by persistent or recurrent labial enlargement, ORAL ULCER, and other orofacial manifestations in the absence of identifiable CROHN DISEASE; or SARCOIDOSIS. There is no consensus on whether orofacial granulomatosis is a distinct clinical disorder or an initial presentation of Crohn disease.

An acute form of MEGACOLON, severe pathological dilatation of the COLON. It is associated with clinical conditions such as ULCERATIVE COLITIS; CROHN DISEASE; AMEBIC DYSENTERY; or CLOSTRIDIUM ENTEROCOLITIS.

Proteins found usually in the cytoplasm or nucleus that specifically bind steroid hormones and trigger changes influencing the behavior of cells. The steroid receptor-steroid hormone complex regulates the transcription of specific genes.

A synthetic steroid that has been used for its anabolic action.

More From BioPortfolio on "A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients"

Quick Search

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system.  Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...


Searches Linking to this Trial